EGFR and neoplasm: Isomoto et al. enrolled 138 EGFR-mutated patients; they demonstrated that the proportion of patients with high PD-L1 expression level (≥ 50%) were increased and the tumor mutation burden was higher than before after EGFR-TKI treatment[26].